Shameem Mahmood
Overview
Explore the profile of Shameem Mahmood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khwaja J, Ravichandran S, Cohen O, Foard D, Low M, Martinez-Naharro A, et al.
Br J Haematol
. 2025 Feb;
PMID: 39980430
Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra-cellular deposition of light-chain aggregates in critical organs. An immunomodulatory agent-based quadruplet including anti-CD38 therapy has not been investigated...
2.
Khwaja J, Ravichandran S, Cohen O, Foard D, Martinez-Naharro A, Venneri L, et al.
Haematologica
. 2025 Jan;
PMID: 39815808
Not available.
3.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, et al.
Amyloid
. 2024 Sep;
31(4):353-355.
PMID: 39311543
No abstract available.
4.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al.
JAMA Cardiol
. 2024 Aug;
9(11):982-989.
PMID: 39167388
Importance: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless...
5.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf M, Foard D, et al.
Br J Haematol
. 2024 Jun;
205(1):138-145.
PMID: 38840512
Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second-line daratumumab-bortezomib-dexamethasone (DVD) in AL amyloidosis in bortezomib-exposed patients. A total of 116 patients...
6.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, et al.
Haematologica
. 2024 Jan;
109(5):1598-1602.
PMID: 38205538
No abstract available.
7.
Bomsztyk J, Ravichandran S, Giles H, Wright N, Berlanga O, Khwaja J, et al.
Blood
. 2024 Jan;
143(13):1259-1268.
PMID: 38194690
Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry-based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC assays...
8.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, et al.
Br J Haematol
. 2024 Jan;
204(5):1811-1815.
PMID: 38171355
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate,...
9.
Razvi Y, Ioannou A, Patel R, Chacko L, Karia N, Riefolo M, et al.
Eur J Heart Fail
. 2023 Nov;
26(2):383-393.
PMID: 37953725
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I)...
10.
Nesr G, Shah R, Kyriakou C, Sive J, Popat R, Yong K, et al.
Leuk Lymphoma
. 2023 Jun;
64(8):1465-1471.
PMID: 37259553
High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) remains the standard consolidation in transplant eligible multiple myeloma (MM) patients. The timing between HDM administration and hematopoietic stem...